Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 162 participants.

Also called NCT04841096

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 162 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04841096
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04841096. Randomized; double masking; primary purpose treatment. Start 2023-03-21 (actual); primary completion 2024-03-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
Intervention (Drug)
A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
Intervention (Drug)
B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
Intervention (Drug)
(A2) Glimepiride/Vildagliptin/Metformin
Intervention (Drug)
(B2) Glimepiride/Vildagliptin/Metformin
Lead sponsor
Laboratorios Silanes S.A. de C.V. (class: industry)

Record details

Record id
cardio:ct-nct04841096
Content hash
bb84830aa903fd599755bea93ee878d4f64ab23323d2b380a7729dfc4a0b74d4